**12. References**

[1] Wolf G, Ziyadeh FN. Renal tubular hypertrophy induced by angiotensin II. Semin Nephrol. 1997;17:448–454

Molecular Mechanisms of Nephro-Protective

1996;10:709–720.

1999;401:82–85.

cells. Hypertension. 1998;32:1083–1088.

Am J Pathol. 1998;153:1825–1837.

the square to learn 2003,9:(5):29-32

science of China 2003, 3:(3)204-206

Nephrol 2003, 14(Suppl 2):S92-S98

Treating Uremia CJIM, 2002;8(3):208-211

protein-1 synthesis. J Immunol. 1998;161:430–439.

Action of HE-86 Liquid Extract in Experimental Chronic Renal Failure 191

[20] Marumo T, Schini Kerth VB, Brandes RP, Busse R. Glucocorticoids inhibit superoxide

[21] Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J.

[22] Ozes O, Mayo L, Gustin J, Pfeffer S, Pfeffer L, Donner D. NF-kappaB activation by

[23] Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M.

[24] Ushio-Fukai M, Alexander R, Akers M, Yin Q, Fujio Y, Walsh K, Griendling K. Reactive

[25] Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor

[26] Morrissey JJ, Klahr S. Rapid communication: enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int. 1997;52:926–933. [27] Ruiz-Ortega M, Bustos C, Hernandez-Presa M, Lorenzo O, Plaza J, Edigo J. Angiotensin

[28] He Li qun, Wang yi, Cao he xin, Li jun. The effect of kangxianling decoction on PDGF-

[29] He liqun、Li jun、Li yi. The effect of "FUZHENGHUOXUE Decoction" on the

[30] LI Jun、HE Li-Qun、LI Yi、HOU Wei-Guo:The Effect of kang xian ling 2 decoction

[31] Wang chen、He liqun. Experimental Study on Effect of Renal Failure Granule in

[32] HE Li-Qun Cai Gan The clinical observation of the JIAN-PI-QIN-HUI prescription on

combination with Chinese and western medicine 2005, 14:(4):270-274 [33] Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V,

[34] Flack JM, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E: Prevention of hypertension

of the CRF rats. J. Chinese medicine 2005. 46:(6):454-457

inflammatory damage in rats. Hypertension. 2000; 35:193–201.

smooth muscle cells. Am J Physiol. 1999;276:H1927–H1934.

vascular smooth muscle cells. J Biol Chem. 1999;274:22699–22704.

anion production and p22 phox mRNA expression in human aortic smooth muscle

tumour necrosis factor requires the Akt serine-threonine kinase. Nature.

Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular

oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in

quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis.

II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kB activation and monocyte chemoattractant

mRNA、TNFα-mRNA expression of CRF Rat renal tissue J. China experiments

expressions of fibronectin and transforming growth factor-βmRNA in renal tissue

on serum lipide metabolism of chronic renal fail rats. J. International medical

spleen deficiency and dampness heat style patients with chronic renal failure J.The

Ganten D, Haller H, Luft FC. NF- B inhibition ameliorates angiotensin II–induced

and its complications: theoretical basis and guidelines for treatment. J Am Soc


[2] Guijarro C, Egido J: Transcription factor-kappa B (NF-kappa B) and renal disease.

[3] Weistuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease?

[4] Yoshioka K, Tohda M, Takemura T, Akano N, Matsubara K, Ooshima A, Maki S.

[5] Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levy BI, Safar ME, Benetos A.

[6] Anderson S, Meyer TW, Renke HG, Brenner BM. Control of glomerular hypertension

[7] Wilson C, Byrom FB. Renal changes in malignant hypertension. Lancet. 1939;i:136–143. [8] Davies PF, Barbee KA, Volin MV, Robotewskyj A, Chen J, Joseph L, Griem ML, Wernick

[9] Jones PL, Crack J, Rabinovitch M. Regulation of tenacin-C, a vascular smooth muscle cell

[12] Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991;68:905–921. [13] Haller H, Park JK, Dragun D, Lippoldt A, Luft FC. Leukocyte infiltration and ICAM-1

[14] Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling.

[15] Roy-Chaudhury P, Hillis G, McDonald S, Simpson JG, Power DA. Importance of the

[16] Ridker PM, Hennekens CH, Roitman Johnson B, Stampfer MJ, Allen J. Plasma

myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92. [17] Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med.

[18] Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-

[19] Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic

renin-angiotensin system. J Am Soc Nephrol. 1991;2:S9–S20.

beta 1, alpha 1 to 6 and alpha V. Kidney Int. 1997;52:103–110.

inflammatory diseases. N Engl J Med. 1997;336:1066–1071.

Distribution of the type I collagen in human kidney diseases in comparison with

Angiotensin-converting enzyme inhibition prevents the increase in aortic collagen

limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–

MN, Jacobs E, Polacek DC, dePaola N, Barakat AI. Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. Ann Rev

survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol. 1997;139:279–293. [10] Isik FF, Gibran NS, Jang YC, Sandell L, Schwartz SM. Vitronectin decreases microvascular endothelial cell apoptosis. J Cell Physiol. 1998;175:149–155. [11] Ingelfinger JR, Dzau VJ. Molecular biology of renal injury: emphasis on the role of the

expression in two-kidney one-clip hypertension. Nephrol Dial Transplant.

tubulointerstitium in human glomerulonephritis, II: distribution of integrin chains

concentration of soluble intercellular adhesion molecule 1 and risks of future

Kidney Int 59: 415–424, 2001

Kidney Int. 1992;41:S33–S37.

Physiol. 1997;59:527–549.

1997;12:899–903.

1998;339:1448–1456.

Hypertension. 1998;31:176–180.

specific gene control. Cell. 1989;58:227–229.

619.

type III collagen. J Pathol. 1990;162:141–148.

in rats. Hypertension. 1994;23:74–82.


Molecular Mechanisms of Nephro-Protective

dependent. Nephron. 2001;87:66–74.

failure. Kidney Int. 1992;42:46–55.

Nephrol. 2003;14:1132–1144.

Nephrol 13: 1773-1787, 2002.

2002;35:1001–1015.

864-876, 1998.

Metab 1998, 24:174-180

receptors. J Hypertens. 1998;16:2027–2037.

Electrolyte Physiol 252: F829-F837, 1987

fibrosis. Contrib Nephrol 2001, 135:153-160

Action of HE-86 Liquid Extract in Experimental Chronic Renal Failure 193

[50] Lombardi DM, Viswanathan M, Vio CP, Saavedra JM, Schwartz SM, Johnson RJ. Renal

[51] Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H, Okabe M,

[52] Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-

[53] Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C, Tharaux PL,

[54] Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, and Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001 [55] Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, and el-Dahr SS.

[57] Zhuo J, Moeller I, Jenkins T, Chai SY, Allen AM, Ohishi M, Mendelsohn FA. Mapping

[58] Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res.

[59] Nath KA, Chmielewski DH, and Hostetter TH. Regulatory role of prostanoids in

[60] Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA,

differentiation of monocytes to macrophages. J Hypertens 17: 537-545, 1999 [61] Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins

[62] Border WA, Noble NA: Interactions of transforming growth factor-beta and

[63] Gaedeke J, Peters H, Noble NA, Border WA: Angiotensin II, TGF-beta and renal

[64] Wolf G: Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte

angiotensin II in renal fibrosis. Hypertension 1998, 31:181-188

and vascular injury induced by exogenous angiotensin II is AT1 receptor-

Terasaki F, Kitaura Y. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart. 2003;89:1236–1242.

independent effect of angiotensin inhibition on vascular lesions of chronic renal

Ardaillou R. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metallo-proteinases. J Am Soc

Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol Renal Physiol 273: F170-F177, 1997 [56] Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey

RM, de Gasparo M, and Cooper ME. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc

tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4

glomerular microcirculation of remnant nephrons. Am J Physiol Renal Fluid

Higaki J, and Ogihara T. Upregulation of renin-angiotensin system during

RC, and Lan HY. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54:


[35] Klahr S, Morrissey J: Progression of chronic renal disease. Am J Kidney Dis 2003,

[36] Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to

[37] Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol Renal Fluid

[38] Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, and

[40] Akai Y, Homma T, Burns KD, Yasuda T, Badr KF, and Harris RC. Mechanical

[41] Lee LK, Meyer TW, Pollock AS, and Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96: 953-964, 1995. [42] Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, and Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001. [43] Van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, and Danser AH. Intrarenal

[44] Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, and Cooper ME.

[45] Pelayo JC, Quan AH, and Shanley PF. Angiotensin II control of the renal

[46] Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, Johnson

[47] Noronha IL, Fujihara CK, and Zatz R. The inflammatory component in progressive

[48] Ford CM, Li S, Pickering JG, Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ.

sinoaortic-denervated rats. J Cardiovasc Pharmacol. 2001;37:6–15.

cyclooxygenase. Am J Physiol Cell Physiol 267: C482-C490, 1994.

Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 64: 2172-2181, 2003 [39] Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-

Pope DF, Couser WG, and Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41:

stretch/relaxation of cultured rat mesangial cells induces protooncogenes and

angiotensin II: interstitial and cellular levels and site of production. Kidney Int 60:

Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy: implications for the pathogenesis of tubulointerstitial fibrosis. Am J

microcirculation in rats with reduced renal mass. Am J Physiol Renal Fluid

RJ, and Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282:

renal disease—are interventions possible (Abstract)? Nephrol Dial Transplant 17:

Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol. 1999;19:1843–1851. [49] Miao CY, Tao X, Gong K, Zhang SH, Chu ZX, Su DF. Arterial remodeling in chronic

angiotensin II antagonists. Kidney Int 2000, 57:1803-1817

Electrolyte Physiol 249: F324-F337, 1985.

41(Suppl 1):S3-S7

297-309, 1992.

2311-2317, 2001

F191-F201, 2002

363, 2002

Pathol 155: 429-440, 1999

Electrolyte Physiol 258: F414-F422, 1990


Molecular Mechanisms of Nephro-Protective

411-452

Immunol 1998; 17: 217-228

Arch 1994; 424: 459-464

43: 682-692

Action of HE-86 Liquid Extract in Experimental Chronic Renal Failure 195

[80] Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A,

[81] Hahn S, Kuemmerle NB, Chan W, Hisano S, Saborio P, Krieg RJ Jr, Chan JC:

[82] Li D, Saldeen T, Romeo F, Mehta JL: Oxidized LDL upregulates angiotensin II type 1

[84] Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev

[85] Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd

[86] Tipping PG, Kitching AR, Cunningham MA, Holdsworth SR. Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens 1999; 8: 281–286 [87] Couser WG. Sensitized cells come of age: a new era in renal immunology with important therapeutic implications. J Am Soc Nephrol 1999; 10: 664–665 [88] Ortiz A, Egidl J. Is there a fole for specific anti-TNF strategies in glomerular diseases.

[89] Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, Maki S. Cellular

[90] Ozen S, Saatci U, Tinaztepe K, Bakkaloglu A, Barut A. Urinary tumor necrosis factor

[91] Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-

[92] Bertani T, Abbate M, Zoja C et al. Tumor necrosis factor induces glomerular damage in

[93] Tomosugi NI, Cashman SJ, Hay H et al. Modulation of antibody-mediated glomerular

[94] Karkar AM, Tam FWK, Steinkasserer A et al. Modulation of antibody-mediated

[95] Karkar AM, Koshino Y, Cashman SJ et al. Passive immunization against TNF alpha and

[96] Fujihara CK, Malheiros DM, Donato JL, Poli A, De Nucci G, and Zatz R.

levels in primary glomerulopathies. Nephron 1994; 66:291-294

localization of inflammatory cytokines in human glomerulonephritis. Virchows

alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;

injury in vivo by bacterial lipo-polysaccharide, tumor necrosis factor and IL-1. J

glomerular injury in vivo by IL-1ra, soluble IL-1 receptor and soluble TNF receptor.

IL-1B protects from LPS enhancing glomerular injury in nephrotoxic nephritis in

Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Am J Physiol Renal Physiol 274: F573-F579, 1998.

renovascular disease. J Am Soc Nephrol 15: 958–966, 2004

tocopherol. J Am Soc Nephrol 9: 2089–2095, 1998

TNF receptor signals cell death. Cell 1993; 74: 845-853

Nephrol Dial Transplant 1995; 10:309-311

the rabbit. Am J Pathol 1989; 134: 419-430

rats. Clin Exp Immunol 1992; 90: 312-318

Immunol 1989; 142: 3083-3090

Kidney Int 1995; 40: 1738-1746

Lerman LO: Antioxidant intervention blunts renal injury in experimental

Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-

receptor expression in cultured human coronary artery endothelial cells: The potential role of transcription factor NF-kappaB. Circulation 102: 1970–1976, 2000 [83] Vassalli P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992; 10:


[65] Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates the proliferation and

[66] Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular

expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437 [67] Wolf G, Zahner G, Schroeder R, Stahl RA: Transforming growth factor beta mediates

murine proximal tubular cells. Nephrol Dial Transplant 1996, 11:263-269 [68] Wolf G, Ziyadeh FN, Stahl RA: Angiotensin II stimulates expression of transforming

[69] Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs

[70] Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME: Angiotensin converting enzyme

[71] Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease:

[72] Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D,

[73] Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE: Urinary

[74] Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade

[75] Barnes PJ, Karin M: Nuclear factor-kappaB: A pivotal transcription factor in chronic

[76] Guijarro C, Egido J: Transcription factor-kappa B (NF-kappa B) and renal disease.

[77] Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B: Melatonin reduces renal interstitial

[78] Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, Vaziri ND: Antioxidant-rich diet

[79] Chade AR, Rodriguez-Porcel M, Herrmann J, Krier JD, Zhu X, Lerman A, Lerman LO:

blockade and sodium restriction. Diabetes Care 2002, 25:1072-1077

inflammatory diseases. N Engl J Med 336 : 1066 –1071, 1997

growth response to angiotensin II. J Clin Invest 1992, 90:456-461

collagen in diabetic vasculopathy. J Hypertens 1998, 16:1603-1609

1992, 140:95-107

Med 1999, 77:556-564

54:1570-1580

39:486-492

605–612, 2003

Nephrol 2003, 14:1816-1824

Kidney Int 59 : 415 –424, 2001

Physiol Renal Physiol 284: F447–454, 2003

hypertensive rats. Hypertension 41: 341–346, 2003

biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol

matrix protein synthesis through induction of transforming growth factor-beta

the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured

growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol

hyperplasia: autocrine transforming growth factor-beta 1 expression determines

inhibition reduces the expression of transforming growth factor-beta(1) and type IV

maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998,

Zanchi C, Abbate M, Ledbetter S, Remuzzi G: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc

transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor

lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002,

inflammation and improves hypertension in spontaneously hypertensive rats. Am J

relieves hypertension and reduces renal immune infiltration in spontaneously

Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension 42:


**12**

*Turkey* 

**The Effects of Asymmetric Dimethylarginine** 

**(ADMA), Nitric Oxide (NO) and Homocysteine** 

**(Hcy) on Progression of Mild Chronic Kidney** 

**Disease (CKD): Relationship Between Clinical** 

*3Dicle University Medical Faculty, Department of Clinical Biochemistry, Diyarbakir* 

Chronic kidney disease (CKD) is a syndrome characterized by the progressive and irrevocable loss of nephrons due to several diseases. Chronic kidney disease has a varying spectrum ranging from normal renal function to uremic syndrome. Actually, the stages of renal failure have interpenetrated each other and it is not possible to draw a clear line between them. The most important reason of mortality and morbidity of patients with CKD are cardiovascular diseases and atherosclerotic complications; cardiac insufficiency 15%, myocardial infarction 10%, pericarditis 3% (1, 2). Development of vascular injury in CKD is caused by both classic (Framingham) risk factors (hypertension, dyslipidemia, smoking, diabetes mellitus) and CKD specific factors (anaemia, secondary hyperparathyroidism etc). Besides, there are papers reporting that recently defined potential risk factors such as homocysteine (Hcy), C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen, soluble intracellular adhesion molecule (sICAM-1), asymmetric dimethyl arginine (ADMA), cardiac specific troponin-I (cTnI), advanced glycation endproducts have a role in the development of accelerated atherosclerosis seen in patients with CKD (2-13). Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase and it is a guanidine analogue of L-arginine aminoacid detectable in human urine

**1. Introduction** 

*Department of Internal Medicine, Division of Gastroenterology, Istanbul* 

*4Dicle University Medical Faculty, Department of Physiology, Diyarbakir* 

*Department of Internal Medicine, Division of Nephrology, Istanbul* 

*Department of Internal Medicine, Division of Nephrology, Istanbul,* 

*Department of Physical Medicine and Rehabilitation, Yalova* 

**and Biochemical Parameters** 

A. Atamer1, S. Alisir Ecder2, Y. Atamer3, Y. Kocyigit4, N. Bozkurt Yigit5 and T. Ecder6

*1Haydarpasa Training and Research Hospital,* 

*5Yalova University, Termal Vocational School,* 

*6Istanbul University, Istanbul Medical Faculty,* 

*2Goztepe Training and Research Hospital,* 

